Patent application number | Description | Published |
20080249149 | Crystalline Forms of Rizatriptan Benzoate - The present invention is directed to the novel polymorphic Form A and Form B of Rizatriptan benzoate, processes for the preparation thereof and pharmaceutical compositions comprising these crystalline forms. | 10-09-2008 |
20080269315 | Crystalline form - The present invention is directed to the novel polymorphic Form F of Atorvastatin calcium, processes for the preparation thereof and pharmaceutical compositions comprising this crystalline form. | 10-30-2008 |
20090042815 | Macrolide Synthesis Process and Solid-State Forms - This invention relates to a method for making macrolides, and, in particular, a method for making optionally substituted 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide and derivatives thereof, as well as uses of macrolides to make medicaments, methods of treatment using macrolides, and methods for making intermediates that, inter alia, may be used to make macrolides. This invention also relates to solvated and non-solvated crystalline forms of 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide, as well as methods for making such crystalline forms, medicaments comprising (or derived from) such crystalline forms, methods for making medicaments comprising (or derived from) such crystalline forms, methods of treatment using such crystalline forms, and kits comprising such crystalline forms. | 02-12-2009 |
20090197826 | P-Toluene Sulfonic Acid Salt of 5-Amino-3-(2'-O-Acetyl-3'-Deoxy-Beta-D-Ribofuranosyl)-3H-Thiazole[4,5-d]p- yrimidine-2-one and Methods for Preparation - The present disclosure relates to p-toluene sulfonic acid salt of 5-amino-3-(2′-O-acetyl-3′-deoxy-beta-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one and to its use in treating conditions such as viral infections, tumors, and cancer. | 08-06-2009 |
20090281162 | Crystalline forms of atorvastatin - The present invention is directed to new crystalline forms of Atorvastatin calcium (2:1), referred to hereinafter as polymorphic Forms X, A, B1, B2, C, D and E. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and pharmaceutical compositions comprising the crystalline forms. | 11-12-2009 |
20100009996 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS - The present invention is directed to a novel methods and compositions for the therapeutic intervention in hyperphenylalaninemia. More specifically, the specification describes methods and compositions for treating various types of phenylketonurias using compositions comprising BH4. Combination therapies of BH4 and other therapeutic regimens are contemplated. | 01-14-2010 |
20100034773 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS - The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus. | 02-11-2010 |
20100099685 | CRYSTALLINE FORMS OF (6R)-L-ERYTHRO-TETRAHYDROBIOPTERIN DIHYDROCHLORIDE - Crystal forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride, hydrates and solvates and processes for their preparation are provided. These crystal forms are either intermediates for the preparation of stable polymorphic form B or are suitable for solid formulations. | 04-22-2010 |
20100240667 | CRYSTALLINE FORMS OF (6R)-L-ERYTHRO-TETRAHYDROBIOPTERIN DIHYDROCHLORIDE - Crystal forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride, hydrates and solvates and processes for their preparation are provided. These crystal forms are either intermediates for the preparation of stable polymorphic form B or are suitable for solid formulations. | 09-23-2010 |
20100286254 | CRYSTALLINE FORMS OF DMXAA SODIUM SALT - The present invention relates to pharmaceutically stable crystalline forms of (5,6-Dimethyl-9-oxo-9H-xanthene-4-yl)acetic acid (DMXAA) sodium salt, processes for preparing those stable crystalline forms; pharmaceutical compositions comprising at least one of those crystalline forms in solid form or in dissolved form and a pharmaceutically acceptable carrier. Disclosed are methods of using those pharmaceutical compositions to treat tumours, optionally in combination with other active pharmaceutical agents. | 11-11-2010 |
20100305329 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its Tartrate Salt and Crystalline Forms - Disclosed herein are methods for synthesizing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)-phenylmethyl)carbamide. Also disclosed herein is the hemi-tartrate salt of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)-phenylmethyl)carbamide and methods for obtaining the salt. Further disclosed are various crystalline forms of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)-phenylmethyl)carbamide and its hemi-tartrate salt including various polymorphs and solvates. | 12-02-2010 |
20110053875 | Macrolide synthesis process and solid-state forms - This invention relates to a method for making macrolides, and, in particular, a method for making optionally substituted 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide and derivatives thereof, as well as uses of macrolides to make medicaments, methods of treatment using macrolides, and methods for making intermediates that, inter alia, may be used to make macrolides. This invention also relates to solvated and non-solvated crystalline forms of 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide, as well as methods for making such crystalline forms, medicaments comprising (or derived from) such crystalline forms, methods for making medicaments comprising (or derived from) such crystalline forms, methods of treatment using such crystalline forms, and kits comprising such crystalline forms. | 03-03-2011 |
20110166344 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS - The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds of Formula I | 07-07-2011 |
20110184179 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its Tartrate Salt and Crystalline Forms - Disclosed herein are methods for synthesizing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)-phenylmethyl)carbamide. Also disclosed herein is the hemi-tartrate salt of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)-phenylmethyl)carbamide and methods for obtaining the salt. Further disclosed are various crystalline forms of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)-phenylmethyl)carbamide and its hemi-tartrate salt including various polymorphs and solvates. | 07-28-2011 |
20120101126 | CRYSTALLINE FORMS OF PITAVASTATIN CALCIUM - The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous form. | 04-26-2012 |
20120108599 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS - The present invention is directed to a novel methods and compositions for the therapeutic intervention in hyperphenylalaninemia. More specifically, the specification describes methods and compositions for treating various types of phenylketonurias using compositions comprising BH4. Combination therapies of BH4 and other therapeutic regimens are contemplated. | 05-03-2012 |
20120142693 | CRYSTALLINE COMPOUND OF 7-[(3R)-3-AMINO-1-OXO-4-(2, 4, 5-TRIFLUORPHENYL)BUTYL]-5, 6, 7, 8-TETRAHYDRO-3-(TRI FLUORMETHYL)-1, 2, 4 -TRIAZOLO[4,3-A]PYRAZIN - A crystalline compound of 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine (INN: Sitagliptin) of formula 1 | 06-07-2012 |
20130053413 | CRYSTALLINE FORMS OF PITAVASTATIN CALCIUM - The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms. | 02-28-2013 |
20130237553 | MULTICOMPONENT SYSTEM OF RESUVASTATIN CALCIUM SALT AND SORBITOL - A novel solid form of Rosuvastatin comprises as the active ingredient a salt of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)-amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid] and sorbitol. The crystal comprising the two components, and minor amounts of water, shows improved properties such as crystal-lization behaviour and stability. | 09-12-2013 |
20140005402 | CRYSTALLINE FORMS OF PITAVASTATIN CALCIUM | 01-02-2014 |
20140031377 | MULTICOMPONENT CRYSTALLINE SYSTEM OF ROSUVASTATIN CALCIUM SALT AND VANILLIN - A novel solid form of Rosuvastatin comprises as the active ingredient a salt of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)-amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid] and vanillin or vanillin derivatives. The crystal comprising the two components, and minor amounts of water, shows improved properties such as crystallization behavior stability and decreased hydroscopic behavior. | 01-30-2014 |
20140121259 | NOVEL CRYSTALLINE ASENAPINE HYDROCHLORIDE SALT FORMS - Novel crystalline HCl salts of Asenapine, methods of their preparation and related pharmaceuticals and treatments are disclosed. | 05-01-2014 |
20140128444 | NOVEL CRYSTALLINE SALTS OF ASENAPINE WITH ORGANIC DI-ACIDS AND TRI-ACIDS - Novel crystalline salts of Asenapine (I) with organic di-acids and tri-acids and to methods of their preparation are disclosed along with related pharmaceutical compositions and methods of treating psychotic diseases or disorders. | 05-08-2014 |
20140135353 | CRYSTALLINE SODIUM SALT OF AN HIV INTEGRASE INHIBITOR - A crystalline sodium salt of a compound of formula I (INN: Raltegravir) | 05-15-2014 |
20140155371 | MULTICOMPONENT CRYSTALLINE SYSTEM OF EZETIMIBE AND PROLINE - Provided is a crystalline composition comprising a mixture of a compound of formula 1 (Ezetimibe) and proline or proline derivatives, or a hydrate/solvate thereof, as well as a process for obtaining the same. And a process for the purification of Ezetimibe is also disclosed. | 06-05-2014 |
20140163083 | NOVEL CRYSTALLINE SALTS OF ASENAPINE - Crystalline Asenapine salts of tartaric acid or succinic acid, wherein the salts are e.g. selected from the group consisting of Asenapine D, L-tartrate hydrate form A, Asenapine D, L-tartrate hydrate form B, Asenapine D, L-tartrate anhydrous form, Asenapine succinate form X, Asenapine succinate form, and Asenapine succinate form II are described as well as related pharmaceutical compositions and related treatment of psychotic diseases or disorders. | 06-12-2014 |
20140194453 | MULTICOMPONENT CRYSTALLINE SYSTEM OF ROSUVASTATIN CALCIUM SALT AND VANILLIN - A novel solid form of Rosuvastatin comprises as the active ingredient a salt of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)-amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid] and vanillin or vanillin derivatives. The crystal comprising the two components, and minor amounts of water, shows improved properties such as crystallization behavior stability and decreased hydroscopic behavior. | 07-10-2014 |
20140323417 | CRYSTALLINE DAPAGLIFLOZIN HYDRATE - A crystalline dapagliflozin hydrate and a process for obtaining the same is described. | 10-30-2014 |
20140364614 | CRYSTALLINE FORMS OF PITAVASTATIN CALCIUM - The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms. | 12-11-2014 |
20150087657 | MULTICOMPONENT CRYSTALLINE SYSTEM OF VORICONAZOLE WITH FUMARIC ACID - A novel solid form of Voriconazole comprises the active ingredient (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol and fumaric acid. The solid composition comprising the two components shows improved properties such as water solubility, crystallization behavior and stability. | 03-26-2015 |